[go: up one dir, main page]

CY1119057T1 - Συνδετες υποδοχεα οπιοειδους και μεθοδοι χρησης και κατασκευης αυτων - Google Patents

Συνδετες υποδοχεα οπιοειδους και μεθοδοι χρησης και κατασκευης αυτων

Info

Publication number
CY1119057T1
CY1119057T1 CY20171100716T CY171100716T CY1119057T1 CY 1119057 T1 CY1119057 T1 CY 1119057T1 CY 20171100716 T CY20171100716 T CY 20171100716T CY 171100716 T CY171100716 T CY 171100716T CY 1119057 T1 CY1119057 T1 CY 1119057T1
Authority
CY
Cyprus
Prior art keywords
manufacture
methods
receptors
connector
connector optional
Prior art date
Application number
CY20171100716T
Other languages
English (en)
Inventor
Dennis Yamashita
Dimitar Gotchev
Philip Pitis
Xiao-Tao Chen
Guodong Liu
Catherine Ck Yuan
Original Assignee
Trevena, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46877853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trevena, Inc. filed Critical Trevena, Inc.
Publication of CY1119057T1 publication Critical patent/CY1119057T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η δήλωση αυτή περιγράφει ενώσεις που μπορεί να δράσουν ως συνδέτες υποδοχέα οπιοειδούς, οι οποίες ενώσεις μπορεί να χρησιμοποιηθούν στη θεραπεία, για παράδειγμα, πόνου και σχετικών με πόνο διαταραχών.
CY20171100716T 2011-03-23 2017-07-04 Συνδετες υποδοχεα οπιοειδους και μεθοδοι χρησης και κατασκευης αυτων CY1119057T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466809P 2011-03-23 2011-03-23
US201261596808P 2012-02-09 2012-02-09
PCT/US2012/030327 WO2012129495A1 (en) 2011-03-23 2012-03-23 Opioid receptor ligands and methods of using and making same

Publications (1)

Publication Number Publication Date
CY1119057T1 true CY1119057T1 (el) 2018-01-10

Family

ID=46877853

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100716T CY1119057T1 (el) 2011-03-23 2017-07-04 Συνδετες υποδοχεα οπιοειδους και μεθοδοι χρησης και κατασκευης αυτων

Country Status (22)

Country Link
US (8) US8835488B2 (el)
EP (3) EP2688403B1 (el)
JP (6) JP5912169B2 (el)
KR (3) KR101991327B1 (el)
CN (1) CN103702561B (el)
AU (2) AU2012230761B2 (el)
CA (1) CA2830742C (el)
CY (1) CY1119057T1 (el)
DK (2) DK3290415T3 (el)
EA (1) EA025456B1 (el)
ES (2) ES2857549T3 (el)
HR (1) HRP20171021T1 (el)
HU (2) HUE032948T2 (el)
IL (4) IL228506A (el)
LT (1) LT2688403T (el)
ME (1) ME02754B (el)
PL (2) PL3290415T3 (el)
PT (2) PT3290415T (el)
RS (1) RS56111B1 (el)
SI (1) SI2688403T1 (el)
SM (1) SMT201700325T1 (el)
WO (1) WO2012129495A1 (el)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3290415T3 (pl) * 2011-03-23 2021-07-19 Trevena, Inc. Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
US10377717B2 (en) 2015-09-16 2019-08-13 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
WO2017049172A1 (en) 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EA201890725A1 (ru) 2015-09-16 2018-08-31 Метакрайн, Инк. Агонисты фарнезоидного х-рецептора и их применение
CN106588899B (zh) * 2015-10-15 2019-11-15 江苏恒瑞医药股份有限公司 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
KR102703513B1 (ko) * 2015-10-15 2024-09-06 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 옥사 스파이로 유도체, 이의 제조방법, 및 의약에서 이의 응용
HK1254672A1 (zh) * 2015-12-14 2019-07-26 Trevena Spv2 Llc 治疗痛觉过敏的方法
WO2017105881A1 (en) * 2015-12-15 2017-06-22 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain
EP3389656A4 (en) * 2015-12-17 2019-06-19 Trevena, Inc. COMBINATIONS OF OPIOID RECEPTOR LIGANDS AND CYTOCHROM P450 INHIBITORS
CN107098876B (zh) * 2016-02-23 2021-04-06 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
JP6889186B2 (ja) * 2016-07-01 2021-06-18 ノイフォルム・ファーマシューティカルズ・インコーポレイテッドＮｅｕｆｏｒｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 疼痛を治療するための重水素化合物
BR112018071678B1 (pt) 2016-08-19 2021-01-26 Gilead Sciences, Inc. compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas
US20200010457A1 (en) * 2016-12-16 2020-01-09 Esteve Pharmaceuticals, S.A. Tetrahydropyran and tetrahydrothiopyran amide derivatives having multimodal activity against pain
CN110446495B (zh) * 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CA3052480A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
PL3609888T3 (pl) 2017-03-15 2025-12-01 Eli Lilly And Company Agoniści receptora farnezoidowego X i ich zastosowanie
JP7174709B2 (ja) 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
KR20190133047A (ko) * 2017-04-14 2019-11-29 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Mor 작용제 및 kor 작용제를 함유하는 약학적 조성물, 및 그의 용도
CN108727347B (zh) * 2017-04-14 2020-06-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
EP3610875B1 (en) * 2017-04-14 2020-10-07 Jiangsu Hengrui Medicine Co., Ltd. Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof
CN115124520A (zh) * 2017-07-04 2022-09-30 四川海思科制药有限公司 阿片受体激动剂及其应用
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
WO2019052557A1 (zh) 2017-09-18 2019-03-21 上海华汇拓医药科技有限公司 μ-阿片受体激动剂及其制备方法和在医药领域的应用
AU2018341782A1 (en) * 2017-09-28 2020-04-16 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing oxaspirocycle derivative, and intermediate thereof
AU2018349930A1 (en) 2017-10-13 2020-04-16 Shandong Luye Pharmaceutical Co., Ltd. 2,6-dioxaspiro (4,5) decane derivatives and preparation method therefor and pharmaceutical applications thereof
CN111065390B (zh) * 2017-12-06 2023-01-24 江苏恒瑞医药股份有限公司 Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途
SG11202007422QA (en) 2018-02-05 2020-09-29 Alkermes Inc Compounds for the treatment of pain
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
CA3281991A1 (en) 2018-02-16 2025-11-29 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
WO2019205983A1 (zh) * 2018-04-28 2019-10-31 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
TW202015678A (zh) * 2018-05-14 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｍｏｒ受體激動劑醫藥組成物
JP2021530523A (ja) 2018-07-16 2021-11-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのカプシド阻害剤
WO2020061113A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN112638906B (zh) * 2018-10-12 2022-05-27 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2020073985A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2020147848A1 (zh) * 2019-01-17 2020-07-23 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
EP4643882A2 (en) 2019-11-26 2025-11-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
CN118221680A (zh) 2020-01-17 2024-06-21 上海海雁医药科技有限公司 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途
KR102847070B1 (ko) 2020-01-17 2025-08-14 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 아자비시클릭 치환된 옥사스피로 유도체, 이의 제조 방법 및 의학적 용도
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
AU2021239956A1 (en) 2020-03-18 2022-10-13 Eli Lilly And Company Formulations of a farnesoid X receptor agonist
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
EP4089088A4 (en) * 2020-08-10 2023-09-13 Chengdu Easton Biopharmaceuticals Co., Ltd. MOR RECEPTOR AGONIST COMPOUND, METHOD FOR PREPARATION THEREOF AND USE THEREOF
CN112694485B (zh) * 2020-09-10 2023-04-07 四川海品信医药科技有限公司 一种阿片受体激动剂噻吩类化合物及其制备方法
US20240109895A1 (en) 2020-12-29 2024-04-04 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Oxaspiro substituted pyrrolopyrazole derivative, intermediate thereof, and preparation method therefor
CN117529481A (zh) * 2021-07-13 2024-02-06 上海海雁医药科技有限公司 Mor受体激动剂的药学上可接受的盐、其多晶型物及其用途
CN115677675B (zh) * 2021-07-21 2025-09-12 成都苑东生物制药股份有限公司 一种6-氧杂螺[4,5]癸烷类化合物的盐、制备方法及用途
EP4375286A4 (en) * 2021-08-02 2024-11-27 Shujing Biopharma Co., Ltd OXASPIRO DERIVATIVE AND MANUFACTURING PROCESS AND USE THEREOF
WO2023030319A1 (zh) * 2021-08-31 2023-03-09 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
FI4445900T3 (fi) 2021-12-03 2025-08-05 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
CN116041336B (zh) * 2022-01-21 2024-07-09 成都硕德药业有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
CN116589451B (zh) * 2022-02-11 2024-07-09 成都硕德药业有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
CN118638109B (zh) * 2024-04-30 2025-10-28 中山大学 一种阿片类药物-奥赛利定的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
US5223530A (en) 1990-07-31 1993-06-29 Sri, International Arylcycloalkanepolyalkylamine ligands
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
AU3192295A (en) * 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
AU6111796A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
GB0130261D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
ES2392200T3 (es) * 2002-09-19 2012-12-05 Eli Lilly & Company Ésteres de diarilo como antagonistas del receptor opiáceo
JP4976134B2 (ja) * 2003-10-01 2012-07-18 アドラー コーポレーション スピロ環複素環誘導体及びそれらを使用する方法
WO2007041341A2 (en) * 2005-09-29 2007-04-12 The Trustees Of Columbia University In The City Of New York Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof
WO2007081966A2 (en) * 2006-01-09 2007-07-19 University Of Southern California Small molecules for treating cancer and abnormal cell proliferation disorders
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
JP2010508358A (ja) * 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
WO2008057856A2 (en) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
WO2009018169A1 (en) 2007-07-27 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
JP5597188B2 (ja) * 2008-03-27 2014-10-01 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスピロ環状シクロヘキサン誘導体
FR2939136B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(heterocycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
FR2967672B1 (fr) * 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
PL3290415T3 (pl) 2011-03-23 2021-07-19 Trevena, Inc. Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania
HK1254672A1 (zh) 2015-12-14 2019-07-26 Trevena Spv2 Llc 治疗痛觉过敏的方法

Also Published As

Publication number Publication date
HUE032948T2 (en) 2017-11-28
SMT201700325T1 (it) 2017-09-07
IL284407B (en) 2022-12-01
IL284407B2 (en) 2023-04-01
JP2021176885A (ja) 2021-11-11
WO2012129495A1 (en) 2012-09-27
KR101991327B1 (ko) 2019-06-20
JP2020073570A (ja) 2020-05-14
US8835488B2 (en) 2014-09-16
NZ615993A (en) 2015-11-27
KR20180100453A (ko) 2018-09-10
IL228506A0 (en) 2013-12-31
ES2632009T3 (es) 2017-09-07
US9849119B2 (en) 2017-12-26
LT2688403T (lt) 2017-07-25
US20180311222A1 (en) 2018-11-01
JP6649341B2 (ja) 2020-02-19
JP5912169B2 (ja) 2016-04-27
EP2688403A1 (en) 2014-01-29
US9044469B2 (en) 2015-06-02
KR20140047599A (ko) 2014-04-22
EP3872076A1 (en) 2021-09-01
US20130331408A1 (en) 2013-12-12
JP6243949B2 (ja) 2017-12-06
US10588898B2 (en) 2020-03-17
US11931350B2 (en) 2024-03-19
PT3290415T (pt) 2021-03-29
US20160250199A1 (en) 2016-09-01
US11077098B2 (en) 2021-08-03
HRP20171021T1 (hr) 2017-09-22
IL284407A (en) 2021-08-31
KR101991326B1 (ko) 2019-06-20
CN103702561A (zh) 2014-04-02
BR112013024136A2 (pt) 2020-01-14
ME02754B (me) 2018-01-20
SI2688403T1 (sl) 2017-08-31
US20170326124A1 (en) 2017-11-16
JP7248750B2 (ja) 2023-03-29
AU2012230761B2 (en) 2016-11-03
IL272165B (en) 2021-07-29
AU2017200745A1 (en) 2017-02-23
PL2688403T3 (pl) 2017-09-29
JP2014508811A (ja) 2014-04-10
US9642842B2 (en) 2017-05-09
JP2023075282A (ja) 2023-05-30
HUE054055T2 (hu) 2021-08-30
CN103702561B (zh) 2017-02-22
EP3290415B1 (en) 2020-12-30
IL228506A (en) 2016-11-30
ES2857549T3 (es) 2021-09-29
IL272165A (en) 2020-03-31
US9309234B2 (en) 2016-04-12
EA201391332A1 (ru) 2014-04-30
KR20190072665A (ko) 2019-06-25
US20220175747A1 (en) 2022-06-09
PL3290415T3 (pl) 2021-07-19
US20150246904A1 (en) 2015-09-03
CA2830742A1 (en) 2012-09-27
JP6923683B2 (ja) 2021-08-25
CA2830742C (en) 2023-03-14
US20120245181A1 (en) 2012-09-27
KR102129247B1 (ko) 2020-07-06
AU2012230761A1 (en) 2013-05-02
AU2017200745B2 (en) 2018-02-22
RS56111B1 (sr) 2017-10-31
EP2688403A4 (en) 2014-10-15
IL243318A0 (en) 2016-02-29
DK3290415T3 (da) 2021-03-22
NZ713143A (en) 2017-05-26
US20190343819A1 (en) 2019-11-14
DK2688403T3 (en) 2017-07-24
EP2688403B1 (en) 2017-05-31
EA025456B1 (ru) 2016-12-30
EP3290415A1 (en) 2018-03-07
PT2688403T (pt) 2017-07-13
JP2016155843A (ja) 2016-09-01
JP2018048193A (ja) 2018-03-29
HK1250984A1 (en) 2019-01-18
IL243318B (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CY1119057T1 (el) Συνδετες υποδοχεα οπιοειδους και μεθοδοι χρησης και κατασκευης αυτων
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1125436T1 (el) Αναστολεις dna-pk
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1120219T1 (el) Ανταγωνιστες της il17c για τη θεραπευτικη αντιμετωπιση φλεγμονωδων διαταραχων
MX2013009679A (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
UA112514C2 (uk) АНТАГОНІСТИ C5aR
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
CY1123007T1 (el) Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
TN2016000057A1 (en) Methods of treating sporadic inclusion body myositis
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
EP3795148C0 (en) USE OF FORMYL PEPTIDE RECEPTOR 2 AGONISTS FOR THE TREATMENT OF INFLAMMATORY OCULAR DISEASES
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
EA201171063A1 (ru) Фармацевтические составы олмесартана
CO6690815A2 (es) Métodos y composiciones para inmunoterapia para enfermedad neural
FR2975600B1 (fr) Agents pour le traitement de tumeurs
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
MX2015017853A (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso.
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3